1. Home
  2. AMBQ vs ZVRA Comparison

AMBQ vs ZVRA Comparison

Compare AMBQ & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMBQ

Ambiq Micro Inc.

HOLD

Current Price

$80.28

Market Cap

594.9M

Sector

Technology

ML Signal

HOLD

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$10.88

Market Cap

653.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMBQ
ZVRA
Founded
2010
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
594.9M
653.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
AMBQ
ZVRA
Price
$80.28
$10.88
Analyst Decision
Buy
Strong Buy
Analyst Count
5
5
Target Price
$42.20
$23.00
AVG Volume (30 Days)
876.5K
1.8M
Earning Date
05-12-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
159.21
EPS
N/A
0.60
Revenue
N/A
$106,470,000.00
Revenue This Year
$41.81
$37.27
Revenue Next Year
$27.98
$53.42
P/E Ratio
N/A
$18.13
Revenue Growth
N/A
350.91
52 Week Low
$22.12
$7.16
52 Week High
$85.72
$13.16

Technical Indicators

Market Signals
Indicator
AMBQ
ZVRA
Relative Strength Index (RSI) 70.86 52.37
Support Level $25.90 $8.26
Resistance Level $85.72 $11.07
Average True Range (ATR) 5.98 0.56
MACD -0.34 0.00
Stochastic Oscillator 74.59 42.30

Price Performance

Historical Comparison
AMBQ
ZVRA

About AMBQ Ambiq Micro Inc.

Ambiq Micro Inc is a fabless semiconductor company that has developed technology based on a patented Sub-threshold Power Optimized Technology (SPOT) platform that significantly reduces the amount of power consumed by integrated circuits. It is a pioneer and provider of ultra-low power semiconductor solutions designed to address the significant power consumption challenges of general purpose and AI compute - especially at the edge.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: